Patrick Dreher
Nurse Practitioner · Fort Lauderdale, FLNPI 1689016214
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Gilead at 32.6% of the total. Reporting peaked in 2021 at $2,373 and has fallen 85.7% since, to $338 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $35.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Novo Nordisk$572
- Amgen$495
- AstraZeneca$462
- Johnson & Johnson$422
- Boehringer Ingelheim$288
- plus $963 from 14 others
What the payments were for
- Food & beverage$4,747100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 33 | $1,547 |
| Novo Nordisk | 11 | $572 |
| Amgen | 26 | $495 |
| AstraZeneca | 8 | $462 |
| Johnson & Johnson | 16 | $422 |
| Boehringer Ingelheim | 4 | $288 |
| Sanofi-aventis U.S. LLC | 8 | $226 |
| Lilly USA, LLC | 9 | $174 |
| AbbVie | 4 | $159 |
| Bayer | 2 | $109 |
| Insulet Corporation | 1 | $61 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Abbott | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Pfizer | 1 | $26 |
| Alkermes, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| GSK | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,747 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 29 | $63,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $1,547 | $63,91929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Fort Lauderdale
- Hilda Ortiz MoralesFort Lauderdale$45K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.